The INNOTEST® β-AMYLOID(1-42) is a solid-phase enzyme immunoassay for the quantitative determination of β-amyloid(1-42) in human cerebrospinal fluid (CSF).
The combined use of CSF-Tau and CSF-β-amyloid(1-42) marker concentrations allows differentiation between Alzheimer’s disease (AD) and normal aging or other neurological diseases such as depression (1-6).
Art. no. 81576 (96T – CE-IVD) - see also Art. no. 81583 (96T - RUO) - Please contact your local Fujirebio representative for the availability of this product in your country.
Features & Benefits
- User-friendly enzyme immunoassay, standard technology
- Generic and color-coded components
- Easily automated on microplate processor (generic components)
- Ready-to-use Calibrators reduce inter and intra run variation
- Run Validation Controls for assay run validation
- Sample volume: 25 µL CSF. Duplicate testing is strongly recommended and requires 2 x 25 µL CSF.
- Limit of Detection: 65 pg/mL
Calibrator range: 62,5 to 4000 pg/mL
- This assay should be used in combination with the Aβ(1-42) CAL-RVC pack, article no. 81577.
- This assay can also be used in combination with the INNOTEST® β-AMYLOID(1-42) HS Conj, article no. 81587 (RUO*) for the quantitative determination of β-amyloid(1-42) in plasma and cell culture supernatants. Use of INNOTEST β-Amyloid article no. 81576 in combination with INNOTEST β-Amyloid(1-42) HS Conj and Aβ(1-42) CAL-RVC pack article no. 81577, implies that no diagnostic claims can be made.
* For research use only. Not for use in diagnostic procedures.
- Andreasen et al. Evaluation of CSF-tau and CSF- Aβ42 as diagnostic markers for Alzheimer’s disease in clinical practice. Arch Neurol 2001;58:373-379.
- Sunderland et al. Decreased b-amyloid1-42 and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer disease. Journal of the American Medical Association 2003;289:2094-2103.
- Hansson et al. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-234
- Mattsson et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302(4): 385-393.
- Tabaraud et al. Alzheimer CSF biomarkers in routine clinical setting. Acta Neurol Scand. 2012; 125(6): 416-23.
- Buchhave et al. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012; 69(1): 98-106.
Additional useful information about Alzheimer’s disease can be found on the following websites: The Alzheimer forum site:
A license regarding amyloid beta antibodies contained in this product under patents US 5750349 has been obtained from Takeda Pharmaceutical Company Limited. Furthermore, a license for the use of amyloid beta monoclonal antibodies contained in this product under patents US 6114133, US7811769, and EP 0792458 has been obtained from Eli Lilly and Company.
These resources are either available in free access or for users holding a Premium eServices account: